CAPN12 Gene Expression as a Molecular Discriminator

November 12, 2026 updated by: Sherine Adly Hashem, South Valley University

CAPN12 Gene Expression as a Molecular Discriminator Between Methotrexate Treated Chronic Plaque Psoriasis and Psoriatic Arthritis

Psoriasis is a chronic immune-mediated inflammatory disease with systemic manifestations. Psoriatic arthritis is an important extracutaneous manifestation that can lead to progressive joint damage and functional disability if not recognized early.

Methotrexate remains a commonly used systemic therapy in both chronic plaque psoriasis and psoriatic arthritis, mainly through anti-inflammatory and immunomodulatory effects.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

Psoriasis is a chronic immune-mediated inflammatory disease with systemic manifestations. Psoriatic arthritis is an important extracutaneous manifestation that can lead to progressive joint damage and functional disability if not recognized early.

Methotrexate remains a commonly used systemic therapy in both chronic plaque psoriasis and psoriatic arthritis, mainly through anti-inflammatory and immunomodulatory effects.

CAPN12 is a calcium-dependent cysteine protease expressed in the epidermis and hair follicles and implicated in skin barrier biology and keratinocyte differentiation. Recent integrative single-cell RNA sequencing and Mendelian randomization work identified CAPN12 among genetically informed psoriasis related candidate genes and linked it to increased psoriasis susceptibility.

The same work reported that these candidate genes were predominantly expressed in CD4+ T cells, supporting the feasibility of peripheral blood mononuclear cell-based expression assessment .

Because methotrexate can modulate immune-cell activity, this study will restrict patient recruitment to methotrexate-treated patients on a stable regimen. This design aims to explore whether CAPN12 expression can discriminate between methotrexate-treated cutaneous-only psoriasis and methotrexate-treated psoriatic arthritis, and whether CAPN12 expression correlates with clinical activity indices.

Study Type

Observational

Enrollment (Estimated)

105

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

      • Qina, Egypt
        • Recruiting
        • South Valley University Hospital
        • Contact:
        • Contact:
        • Sub-Investigator:
          • Shimaa Saber Ahmed, M.D

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 70 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

  • Type of the study: Case-control molecular study.
  • Study Setting: Qena University Hospital, Department of Dermatology, Venereology& Andrology and Rheumatology Clinics.
  • Study subjects: This study will include adult participants recruited from the outpatient Dermatology and Rheumatology Clinics.
  • Receiver operating characteristic curve analysis will be used to evaluate the diagnostic performance of CAPN12 expression.
  • Multivariate logistic regression may be performed to test whether CAPN12 expression is independently associated with psoriatic arthritis status.

Description

Inclusion Criteria:

  • Patients aged 18 -70 years.
  • The severity of cutaneous affection is categorized according to PASI score into PASI 7-12 (moderate severity), and PASI > 12 (severe severity).
  • Confirmed diagnosis: Psoriasis vulgaris (PsV) or Psoriatic arthritis (PsA) diagnosed by a dermatologist/rheumatologist.
  • Willingness to participate: Signed informed consent.
  • Patients on stable dose of methotrexate (MTX) therapy.
  • Availability for follow-up: Patients must be willing and able to attend scheduled visit.

Exclusion Criteria:

  • Patients with other autoimmune conditions (e.g., rheumatoid arthritis, systemic lupus erythematosus).
  • Pregnancy and lactation.
  • Patients currently undergoing immunosuppressive or systemic therapies.
  • Patients with known genetic disorders affect immune system function.
  • Patients with liver or kidney impairment.
  • Patients with allergy or contraindication to methotrexate.
  • Patients with active or uncontrolled infections, including chronic infections like tuberculosis.
  • Previous genetic analysis: Patients who have previously undergone genetic analysis for the CAPN12 gene expression.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: CASE_CONTROL
  • Time Perspectives: PROSPECTIVE

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Chronic plaque psoriasis group

About 35 patients suffering from chronic plaque psoriasis and clinically diagnosed chronic plaque psoriasis receiving a stable methotrexate regimen for at least 12 weeks, with no clinical evidence of psoriatic arthritis.The recommended starting dose for a patient with no risk factors is 10 to 20 mg/wk, the therapeutic dose for most patients is 15 mg/wk, and the maximum dose is between 20 - 25 mg/wk.

to evaluate CAPN12 gene expression as a potential molecular discriminator between methotrexate-treated chronic plaque psoriasis patients and methotrexate treated psoriatic arthritis patients.

Other Names:
  • CAPN12 gene expression
Psoriatic arthritis group

About 35 patients suffering from Psoriatic arthritis and diagnosed with psoriatic arthritis according to the Classification Criteria for Psoriatic Arthritis (CASPAR) and receiving a stable methotrexate regimen for at least 12 weeks.The recommended starting dose for a patient with no risk factors is 10 to 20 mg/wk, the therapeutic dose for most patients is 15 mg/wk, and the maximum dose is between 20 - 25 mg/wk.

to evaluate CAPN12 gene expression as a potential molecular discriminator between methotrexate-treated chronic plaque psoriasis patients and methotrexate treated psoriatic arthritis patients.

Other Names:
  • CAPN12 gene expression
Healthy Control group

About 35 participants inwhich age- and sex-matched apparently healthy individuals with no history of psoriasis, psoriatic arthritis, other autoimmune or chronic inflammatory diseases, and no history of methotrexate therapy.

to evaluate CAPN12 gene expression as a potential molecular discriminator between methotrexate-treated chronic plaque psoriasis patients and methotrexate treated psoriatic arthritis patients.

Other Names:
  • CAPN12 gene expression

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
CAPN12 mRNA expression
Time Frame: 3 Months

Assessment of the Difference in relative CAPN12 mRNA expression among the three studied groups.

3 Months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Pain Relief
Time Frame: 3 Months

Assessment of the patients of the study from the pain after treatment using Visual Analogue Scale (VAS) where as 0 for none up to 10 for very severe

3 Months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Study Chair: Eisa Mohammed Hegazy, M.D, Professor of Dermatology,Venereology and Andrology,Faculty of Medicine
  • Study Director: Marwa Alyan Abdelaziz Mohammed, M.D, Lecturer of Dermatology,Venereology and Andrology,Faculty of Medicine

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 1, 2026

Primary Completion (Estimated)

October 1, 2027

Study Completion (Estimated)

October 10, 2027

Study Registration Dates

First Submitted

November 12, 2026

First Submitted That Met QC Criteria

November 12, 2026

First Posted (Actual)

November 18, 2026

Study Record Updates

Last Update Posted (Actual)

November 18, 2026

Last Update Submitted That Met QC Criteria

November 12, 2026

Last Verified

October 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • CAPN12 Gene Expression

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.